摘要
目的：探讨重组人生长激素治疗特发性矮小症的临床疗效及安全性。方法：选取2010年6月至2012年12月我院儿科诊治的特发性矮小症患儿70例，采用随机数表法将患儿分成两组各35例，对照组给予营养支持，并补充定量钙及赖氨基醇维生素B。治疗组在对照组治疗的基础上于每晚临睡前1h给予皮下注射重组人生长激素0．15U／（kg·d），连续治疗6～18个月，比较两组患儿治疗前后的生长速度（GV）、骨龄（BA）、骨龄对应的身高标准差分值（HtSDSBA）、年龄对应的身高标准差分值（HtSDSCA）、骨龄／实际年龄（BA／CA）、预测成年身高（PAH）变化，并观察不良反应。结果：两组惠儿治疗前各项指标比较差异无统计学意义（P〉0．05），治疗后6个月、12个月、18个月治疗组GV、HtSDSBA、HtSDSCA、PAH与对照组比较差异有统计学意义（P〈0．05）；两组治疗后6个月、12个月、18个月BA、BA／CA比较差异无统计学意义（P〉0．05）；治疗组在治疗期间出现注射部位皮肤红肿1例，为一过性，停药后自行消失，肝肾功能、血常规、尿常规、血糖、甲状腺功能未见异常。结论：重组人生长激素治疗特发性矮小症安全、有效，可有效增加患儿生长速度，对骨龄的增长不明显，值得在临床上推广使用。
Objective： To analyze the clinical efficacy and safety of recombinant human growth hormone in the treatment of idiopathic short stature. Methods： Seventy cases of idiopathic short stature children from June 2010 to December 2012 were divided into two groups by using random number table method. Each group had 35 cases. Both groups received nutritional support, adding quantitative calcium and vitamin B12 lysine amino alcohols; The treatment group were given subcutaneous injection of 0. 15 U/（kg ~ d） recombinant human growth hormone every night one hour before going to sleep. After consecutive treatment for 6 - 18 months, the growth velocity （GV）, bone age （BA）, bone age corresponding to the height standard deviation score （HtSDSBA）, the age of the corresponding height standard deviation score （HtSDSCA） , bone age/actual age （BA/CA） , and the prediction of adult height （PAH） of the two groups were compared, and the adverse reactions were observed. Results： After treatment, compared with the control group, the differences in GV, HtSDSBA, HtSDSCA, and PAH of the treatment group had statistical significance （P〈0.05） ; BA, BA/CA of the two groups after treatment had no significant difference （P〉0.05） ; one case had inflamed skin at injection site in the treatment group during the treatment period; it was disappeared after the medication was stopped, and the results of liver, kidney and thyroid function tests, blood and urine routine tests and blood sugar of this patient were normal. Conclusions： The recombinant human growth hormone in the treatment of idiopathic short stature is safe and effective, which can effectively increase the growth rate of bone age. It is worthy of promotion in clinical use.
出处
《儿科药学杂志》
CAS
2014年第3期31-33,共3页
Journal of Pediatric Pharmacy
关键词
重组人生长激素
特发性矮小症
儿童
Recombinant human growth hormone
Idiopathic short stature
Children
